Article

Pathway Analysis Revealed Potential Diverse Health Impacts of Flavonoids that Bind Estrogen Receptors

Hao Ye †, Hui Wen Ng, Sugunadevi Sakkiah, Weigong Ge, Roger Perkins, Weida Tong and Huixiao Hong *

Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, AR 72079, USA; haoye.ecust@gmail.com (H.Y.); Huiwen.Ng@fda.hhs.gov (H.W.N.); Suguna.Sakkiah@fda.hhs.gov (S.S.); weigong.ge@fda.hhs.gov (W.G.); Roger.Perkins@fda.hhs.gov (R.P.); weida.tong@fda.hhs.gov (W.T.)

* Correspondence: Huixiao.Hong@fda.hhs.gov; Tel.: +1-870-543-7296; Fax: +1-870-543-7854
† Current address: Oncology Business Unit, WuXi AppTec Co., Ltd., Shanghai 200131, China.

Academic Editor: Paul B. Tchounwou
Received: 17 February 2016; Accepted: 22 March 2016; Published: 26 March 2016

Abstract: Flavonoids are frequently used as dietary supplements in the absence of research evidence regarding health benefits or toxicity. Furthermore, ingested doses could far exceed those received from diet in the course of normal living. Some flavonoids exhibit binding to estrogen receptors (ERs) with consequential vigilance by regulatory authorities at the U.S. EPA and FDA. Regulatory authorities must consider both beneficial claims and potential adverse effects, warranting the increases in research that has spanned almost two decades. Here, we report pathway enrichment of 14 targets from the Comparative Toxicogenomics Database (CTD) and the Herbal Ingredients’ Targets (HIT) database for 22 flavonoids that bind ERs. The selected flavonoids are confirmed ER binders from our earlier studies, and were here found in mainly involved in three types of biological processes, ER regulation, estrogen metabolism and synthesis, and apoptosis. Besides cancers, we conjecture that the flavonoids may affect several diseases via apoptosis pathways. Diseases such as amyotrophic lateral sclerosis, viral myocarditis and non-alcoholic fatty liver disease could be implicated. More generally, apoptosis processes may be importantly evolved biological functions of flavonoids that bind ERs and high dose ingestion of those flavonoids could adversely disrupt the cellular apoptosis process.

Keywords: estrogen receptor; flavonoids; target; gene; pathway analysis

1. Introduction

Flavonoids are a group of natural compounds sharing the basic parent structure of 2-phenyl-1,4-benzopyrone. They are widely distributed in modern human diets, including fruit, vegetable, tea and even wine [1,2], as they have been across geologic eras in the history of animals. A huge amount of literature supports the importance of flavonoids in the appearance and rise of higher primates. However, in the interest of human health, science must ask when there is too much of a good thing.

Flavonoids can be generally grouped into six chemical classes: flavones, flavonols, flavanones, flavanols, anthocyanidins and isoflavones [3]. Epidemiologic studies are strongly supportive that flavonoids-enriched diets promote health in diverse ways through diverse mechanisms—specifically, reduced cancer risk [4,5], antioxidation effects [6,7], mitigation of cardiovascular diseases [8,9], anti-inflammatory properties [10], counteraction of obesity [11], reinforce cognition [12], and potential addition to many beneficial effects of estrogen activity across tissue types [13,14]. Neither U.S. nor Eurozone regulators promulgate recommendations with respect to flavonoids, either official or unofficial. Regulatory decisions would require the same solid science basis and data as for drug
clinical trials. Such study designs would normally be protracted and expensive and require rigor such as double-blind controlled experiments.

The supplement industry is a conglomeration of small to large companies comprising product pipelines. The companies are required to ensure that products are safe, but not to prove so with rigorous testing—so they do not. The Food and Drug Administration (FDA) will only take action if strong evidence appears of harm, or if specific marketing claims are deemed by the FDA to be untruthful and not misleading—see Dietary Supplement Health and Education Act of 1994 [15]. Thus, most claims are vague and generally in order to conform, while a vast amount of literature constituting conjecture, pseudoscience and even fraud is readily available to the public in venues from print to online that fosters self-medication, despite the Federal Trade Commission’s duty to control its truthfulness. Unfortunately, companies’ intent on deception can often deceive for a long and prosperous period of time. Regulatory authorities expend great effort to provide cautionary science-based education, but many consumers may simply hear what they want to hear in slick and obfuscatory off-label marketing. Recently, with academic studies raising alarms, some U.S. State Attorney Generals have initiated their own studies, with alarming findings that a large proportion of supplement products do not even contain the purported bioactive components, evidence that outright fraud is rampant. Caveat emptor seems to be the consumer’s smartest tactic when choosing supplements.

The health conscious public has become increasing aware of the potential health benefits of endocrine active chemicals such as the flavonoids. The active chemicals have been conserved across many plants and especially vertebrate metazoans through co-evolution. In certain cases, plants use isoflavones as biochemical defense weapons against predation. Not surprisingly, the market responded with various flavonoids compound formulations. In some formulations, ingested dose could be considered as high. For example, the recommended daily dose of quercetin supplement is up to 1136–2272 mg [16], compared to nominal total isoflavone in humans in 27.80 mg per day [17], the later common in high soy diets. Such a step increase in a bioactive chemical is justifiably concerning. Moreover, studies [18–20] have increased adverse effect concerns due to flavonoid-drug interactions. As a specific example, flavonoids may influence the multidrug resistance process through ATP-binding cassette (ABC) transporters [21]. Since the dietary supplements of flavonoids are not classified as drugs, their potential toxicities via interactions have not been adequately evaluated and are certainly needed.

The endocrine system contains glands that produce and release hormones that are carried to distant target organs in the body through circulation. A wide range of tissue-dependent biological responses are resulted from hormone binding endocrine receptor complexes, such as growth and development [22,23], vascular smooth muscle contraction [24] and reproduction [25]. Simply put, the normal endocrine system is paramount to coordinating and maintaining reproduction, development, wide-ranging body functions, and maintaining homeostasis in general. The so-called endocrine disruptors (EDs) are chemicals (normally exogenous) that interfere with normal endocrine function to an extent to cause adverse effects. Some scientists prefer using the terminology endocrine-active, but that may be drawing a distinction where there is no difference, as an exogenous hormone exposure superimposes on already active homeostatic hormone levels. Regardless whether you label them disruptors or active, significant concerns, public and regulatory, about EDs launched a major effort by the U.S. Environmental Protection Agency (EPA) named the Endocrine Disruptor Screening Program (EDSP) [26] to evaluate tens of thousands of natural and man-made chemicals for endocrine activity; many suspected industrial chemicals are lipophilic and produced in enormous quantity, ultimately persisting in food-chains worldwide. The estrogen receptors (ERs) are arguably the most important receptors in the endocrine system and are involved prodigious biological processes, and especially sensitive windows of time associated with reproduction and development to the adulthood system [27,28]. Many studies have shown that ERs are important to many mechanisms—transcription mediated or not—that exert therapeutic effects on neurodegenerative diseases [29,30], cancers [31,32], cardiovascular diseases [33,34], obesity [35,36] and osteoporosis [37], among others. It is hardly surprising then that homology and mutation rate studies infer that the early protein ancestors date to
the early time on earth when metazoans were first arising. They are highly preserved across vertebrates. The awareness of the criticality of the nuclear receptors proteins prompted the U.S. FDA to build a comprehensive Estrogenic Activity Database (EADB) [38] in the Endocrine Disruptors Knowledge Base (EDKB) [39–41]. The aggregation of diverse assay data types into a single chemical-centric database was deemed essential to foster basic and regulatory science and the building of in silico predictive models for assessing endocrine activity in the FDA-regulated products and environmental chemicals [42–48]. Here, we utilize EADB curated data along with target genes’ data from public databases to more closely examine putative and possible beneficial and toxicity profiles of flavonoids that are ER binders.

2. Materials and Methods

2.1. Study Design

Figure 1 depicts our study’s workflow. We retrieved from the EADB 22 flavonoids that exhibited estrogen receptor binding activity in our own validated relative binding affinity assays [39]. Then, direct binding targets of these flavonoids were taken from the Comparative Toxicogenomics Database (CTD) [40] and the Herbal Ingredients’ Targets (HIT) database [41]. In order to reduce the false positive rate, we used only the targets common to CTD and HIT. We then mapped the targets to biological process pathways and disease pathways in Kyoto Encyclopedia of Genes and Genomes (KEGG). Finally, the hypergeometric statistics model was used to identify the enriched pathways of the selected common targets.

![Figure 1. Overview of the study design.](image-url)
2.2. Flavonoids with ER Binding Activity and Their Targets

We retrieved 22 flavonoid’s ER binding activity data from our earlier competitive binding assays [39]. Basic information of the 22 flavonoids—including Chemistry Abstract Service (CAS) number, structure, log (relative binding affinity)—is listed as Table 1. The structures of the 22 flavonoids are shown in Figure 2.

![Structures of flavonoids.](image)

**Table 1.** Basic information of flavonoids with estrogen receptor (ER) binding activity.

| ID | Name                  | CAS      | ER Activity | Number of Targets |
|----|-----------------------|----------|-------------|------------------|
| 1  | Rutin                 | 153-18-4 | −4.09       | 3 5              |
| 2  | 7-Hydroxyflavanone    | 6515-36-2| −3.73       | 0 2              |
| 3  | 6-Hydroxyflavone      | 6665-83-4| −3.41       | 0 1              |
| 4  | Morin                 | 480-16-0 | −3.09       | 4 1              |
| 5  | Baicalein             | 491-67-8 | −3.05       | 4 4              |
| 6  | 6-Hydroxyflavanone    | 4250-77-5| −3.05       | 0 0              |
| 7  | Formononetin          | 485-72-3 | −2.98       | 2 3              |
| 8  | 3-hydroxyflavanone    | 92496-65-6| −2.78       | 0 2              |
Table 1. Cont.

| ID | Name                     | CAS       | ER Activity | Number of Targets |
|----|--------------------------|-----------|-------------|------------------|
| 9  | Myricetin                | 529-44-2  | −2.75       | HIT 9 CTD 2      |
| 10 | Prunetin                 | 552-59-0  | −2.74       | 0 0              |
| 11 | 4-hydroxyflavanone       | 6515-37-3 | −2.65       | 0 3              |
| 12 | Biochanin A              | 491-80-5  | −2.37       | 0 12             |
| 13 | Fisetin                  | 528-48-3  | −2.35       | 8 2              |
| 14 | 3,4,7-Trihydroxyisoflavone | 485-63-2 | −2.35       | 0 0              |
| 15 | Naringenin               | 480-41-1  | −2.13       | 4 12             |
| 16 | Daidzein                 | 486-66-8  | −1.65       | 12 12            |
| 17 | Kaempferol               | 520-18-3  | −1.61       | 12 20            |
| 18 | Apigenin                 | 520-36-5  | −1.55       | 15 16            |
| 19 | 4,6-Dihydroxyflavone     | 63046-09-3| −0.82       | 0 0              |
| 20 | Equl                     | 531-95-3  | −0.82       | 0 7              |
| 21 | Genistein                | 446-72-0  | −0.36       | 16 37            |
| 22 | 3,6,4-Trihydroxyflavone  | 253195-19-6| −0.35       | 0 0              |

2.2.1. Targets from CTD

CTD [40] is a comprehensive database of curated information on environment exposure effects on human health. It comprises three major categories of data: chemical-gene/protein, chemical-disease and gene-disease relationships. Data are the result of manual curation and text-mining of the literature. We carried out searches of the 22 flavonoids one by one in the CTD website [49]. Only the manually curated chemical-gene records with “binding interaction” were selected. From this, we retrieved 65 targets for 17 flavonoids in CTD that are listed in Table 2.

Table 2. Targets of flavonoids selected from the EADB retrieved from the CTD.

| Gene (Entrz ID) | Chemical IDs | Gene (Entrz ID) | Chemical IDs |
|-----------------|--------------|-----------------|--------------|
| ABCC2 (1244)    | 21           | FOXO3 (2309)    | 21           |
| AFP (174)       | 2, 5, 8, 9, 11, 13, 15, 17, 18, 20 | GPER1 (2852) | 21           |
| AHR (196)       | 5, 12, 15, 16, 17, 18, 21 | GREB1 (9687) | 17, 21       |
| AIP (9049)      | 17, 18       | HIF1A (3091)   | 21           |
| AKR1C1 (1645)   | 15           | HIST3H3 (8290) | 21           |
| AKT1 (207)      | 21           | JUN (3725)     | 17, 18       |
| ALB (213)       | 1, 7         | JUND (3727)    | 21           |
| ALPL (249)      | 15, 16, 21   | MAP2K1 (5604)  | 9            |
| APP (351)       | 4, 5, 17     | NCOA1 (8648)   | 12, 21       |
| AR (367)        | 3, 11, 13, 20, 21 | NCOA2 (10499) | 16, 21       |
| ARNT (405)      | 15, 17, 18, 21 | NCOA3 (8202)  | 17           |
| BAX (581)       | 17           | NFKBIA (4792)  | 18           |
| BBC3 (27113)    | 17           | NFKBIB (4793)  | 18           |
| BCL2L1 (598)    | 17           | NOS3 (4846)    | 20           |
| CASP3 (836)     | 1            | NR1H3 (10062)  | 21           |
| CASP8 (841)     | 1            | NR1I2 (8856)   | 16, 21       |
| CAV1 (857)      | 20           | NR3C1 (2908)   | 21           |
| CBR1 (873)      | 1, 21        | NRIPI1 (8204)  | 21           |
| CCND1 (595)     | 1            | PGR (5241)     | 12, 17, 18   |
| CDK2 (1017)     | 16           | PNRC1 (10957)  | 12, 16, 21   |
| CDKN1A (1026)   | 16           | PPARG (5468)   | 17, 18       |
| CYLD (1540)     | 21           | PTEN (5728)    | 21           |
Table 2. Cont.

| Gene (Entrez ID) | Chemical IDs | Gene (Entrez ID) | Chemical IDs |
|------------------|--------------|------------------|--------------|
| CYP19A1 (1588)   | 12, 15       | RORC (6097)      | 12           |
| CYP1A1 (1543)    | 12, 15, 17, 18 | RXRA (6256)     | 21           |
| CYP1B1 (1545)    | 5, 15, 17, 18, 21 | SHBG (6462)   | 2, 8, 11, 15, 18, 20, 21 |
| EDN1 (1906)      | 21           | S1 (6476)       | 15           |
| ESR1 (2099)      | 7, 12, 15, 16, 17, 18, 20, 21 | SIRT1 (23411) | 21           |
| ESR2 (2100)      | 7, 12, 15, 16, 17, 18, 20, 21 | SP1 (6667)     | 21           |
| ESRRA (2101)     | 12, 16, 21   | SULT2A1 (6822)  | 21           |
| ESRBB (2103)     | 12, 16, 21   | TNC (7124)      | 17, 18       |
| ESRRG (2104)     | 12, 16, 21   | TP53 (7157)     | 17, 21       |
| FOS (2353)       | 17, 18       | TSC22D3 (1831)  | 21           |
|                  |              | VDR (7421)      | 21           |

2.2.2. Targets from HIT

HIT [41] target information came from manual curation of herbal ingredient chemicals from PubMed abstracts. It covers the relationships of herb-compound, compound-gene, and Traditional Chinese Medicine (TCM) formula-herb. With respect to compound-gene relationships, the targets were divided into indirect targets and direct targets based on the binding information. In this study, we retrieved the direct targets information through keyword search of the 22 flavonoids at the HIT website [50]. Finally, 74 direct targets were retrieved for 11 flavonoids contained in HIT, as listed in Table 3.

Table 3. Targets of flavonoids selected from the EADB retrieved from the HIT.

| Gene (Entrez ID) | Chemical IDs | Gene (Entrez ID) | Chemical IDs |
|------------------|--------------|------------------|--------------|
| ADH1B (125)      | 16           | GBA (2629)       | 21           |
| ADH1C (126)      | 16           | GSK3B (2932)     | 18           |
| ADH4 (127)       | 16           | HDAC1 (3065)     | 18           |
| AHR (196)        | 17           | HSD17B7 (51478)  | 18           |
| AKTIP (64400)    | 9, 21        | IL4 (3565)       | 13, 18       |
| ALB (213)        | 21           | JAK1 (3716)      | 9            |
| ALGS (29880)     | 18           | LOX (4015)       | 5            |
| ALOX12 (239)     | 5            | MAP2K4 (6416)    | 21           |
| ALOX5 (240)      | 4            | MGAM (8972)      | 16           |
| APEX1 (328)      | 21           | MMP1 (4312)      | 17           |
| AR (367)         | 13, 21       | MMP2 (4313)      | 9            |
| ATP1A1 (476)     | 9            | MPO (4353)       | 1            |
| AURKB (9212)     | 13           | MTOR (2475)      | 13           |
| BCHE (590)       | 15           | NOS2 (4843)      | 5, 17        |
| BDNF (627)       | 16           | NR1I2 (8856)     | 16           |
| BTK (695)        | 21           | ORL1 (4973)      | 18           |
| CAST3 (836)      | 9, 16        | PARP1 (142)      | 9, 13        |
| CAV1 (857)       | 16           | PIP4K2A (5305)   | 4            |
| CD38 (952)       | 18           | PKD2 (5311)      | 15           |
| CDK4 (1019)      | 13           | PPARA (5456)     | 21           |
| CDK9 (1025)      | 18           | PPARG (5468)     | 17           |
| CFT1 (1080)      | 21           | PEP3CA (5530)    | 17           |
| COMT (1312)      | 9            | PROCR (10544)    | 1            |
| CXCR4 (7852)     | 18           | PTK2B (2185)     | 16           |
| CYP19A1 (1588)   | 15, 18       | RAD51 (5888)     | 5            |
| CYP1A1 (1543)    | 17           | RELA (5970)      | 17           |
| CYP1A2 (1544)    | 17           | RPS9 (6203)      | 18           |
| CYP1B1 (1545)    | 17           | SCD (6319)       | 18           |
| DNMT1 (1786)     | 21           | SIRT1 (23411)    | 13           |
### Table 3. Cont.

| Gene (Entrz ID) | Chemical IDs | Gene (Entrz ID) | Chemical IDs |
|----------------|--------------|----------------|--------------|
| DPP4 (1803)    | 18           | SLC2A1 (6513)  | 21           |
| EGFR (1956)    | 21           | SLC52A1 (55065)| 16           |
| EPHB2 (2048)   | 16           | STAT3 (6774)   | 9            |
| ESR1 (2099)    | 7, 9, 15, 16, 17, 21 | SYK (6850)     | 21           |
| ESR2 (2100)    | 7, 17, 21    | TNF (7124)     | 1, 17        |
| FABP4 (2167)   | 18           | TOP1 (7150)    | 13           |
| FAS (355)      | 4            | VEGFA (7422)   | 18           |
| FASN (2194)    | 21           | XDH (7498)     | 4            |

#### 2.3. Pathway Data

The KEGG [42] pathway database contains a series of manually drawn pathway maps representing our current knowledge on molecular interactions. It is one of most frequently used reference knowledge databases for gene function annotation. The KEGG pathway database contains two major types of pathways: biological process pathways (including metabolism, genetic information processing, environmental information processing, cellular processes, and organismal systems) and human disease pathways. In this study, we downloaded the XML files of each pathway map. Then, python scripts were developed to parse the genes in the pathway maps from the original XML files. In the end, we collected 223 biological process pathways and 71 human disease pathways, covering 6088 genes and 2459 genes, respectively (updated by 22th October 2015), for use in pathway enrichment calculations.

#### 2.4. Pathway Enrichment Analysis

Pathway enrichment analysis is the predominant approach used for deciphering the biological functions associated with a list of genes [43]. In this study, the targets of estrogenic flavonoids common to CTD and HIT were used as the input gene list to detect the potential biological functions that might be influenced by flavonoids that are ER binders. The targets were first mapped to the biological process pathways and the human disease pathways. Then pathway enrichment was calculated on the pathways containing common targets. The enrichment calculation used the hypergeometric statistical model to identify the enriched pathways in the manner described in our previously reported studies [44–47].

For each pathway \(i\), we calculated a \(p\)-value using Equation (I) and an enrichment factor (EF) using Equation (II).

\[
p = 1 - \sum_{x=0}^{x=a} \binom{n}{x} \binom{M-n}{a-x} \tag{I}
\]

\[
EF = \frac{a}{n} \cdot \frac{A}{M} \tag{II}
\]

where \(a\) is the number of common targets associated with pathway \(i\); \(n\) is the number of all genes in pathway \(i\); \(M\) indicates the number of all genes associated with all pathways containing the common targets; and \(A\) is the number of all common targets covered by the pathways.

In the enrichment analysis, the criteria \(a \geq 2\) (the enriched pathways contain at least two common targets), \(EF \geq 3\) and \(p\)-value \(\leq 0.05\) were used to designate enriched pathways.
3. Results

3.1. Common Targets

Table 4 lists the common flavonoids target hits for CTD and HIT (for the 22 flavonoids and 14 target genes common to both databases). Cytochrome CYP450 family and nuclear hormone receptors are the two major gene families associated with targets. As expected, genes ESR1 and ESR2 were among the common targets, considering that all of the 22 flavonoids are ER binders. CYP450 genes involve the metabolic process of flavonoids. Other targets provide clues for discovering new putative functions of the flavonoids.

Table 4. Common targets to CTD and HIT.

| Target     | Entrz Gene ID | Gene Family                        |
|------------|---------------|------------------------------------|
| CYP1A1     | 1543          | Cytochrome P450 family 1           |
| CYP1B1     | 1545          | Cytochrome P450 family 1           |
| CYP19A1    | 1588          | Cytochrome P450 family 19          |
| AR         | 367           | Nuclear hormone receptors          |
| ESR1       | 2099          | Nuclear hormone receptors          |
| ESR2       | 2100          | Nuclear hormone receptors          |
| NR1I2      | 8856          | Nuclear hormone receptors          |
| PPARG      | 5468          | Nuclear hormone receptors          |
| TNF        | 7124          | Tumor necrosis factor superfamily  |
| ALB        | 213           | Unglycosylated serum protein       |
| AHR        | 196           | Basic helix-loop-helix proteins    |
| CASP3      | 836           | Caspases                           |
| CAV1       | 857           | Membrane proteins                  |
| SIRT1      | 23411         | Sirtuins                           |

3.2. Biological Process Pathways of the Common Targets

After mapping the 14 common targets to the 223 biological process pathways of KEGG, we found 11 common targets were associated with 35 biological process pathways. Among the 35 biological process pathways, eight were designated as enriched based our stated criteria, i.e., two or more common targets, \( p \)-value \( \leq 0.05 \) and \( \text{EF} \geq 3 \). The pathways designated as enriched are listed in Table 5. Expectedly, given that all 22 flavonoids are ER binders, the estrogen signaling pathway where ER is the mediating receptor was enriched. The other enriched pathways suggest that flavonoid ER binders potentially affect other biological processes in three categories: ER regulated processes; estrogen metabolism and synthesis; and cellular apoptosis.

Table 5. Enriched biological process pathways.

| Pathway                             | Category                        | EF      | \( p \) Value |
|-------------------------------------|---------------------------------|---------|---------------|
| Tryptophan metabolism               | Amino acid metabolism           | 8.3203  | 0.0014        |
| Apoptosis                           | Cell growth and death           | 4.0634  | 0.0110        |
| Ovarian steroidogenesis             | Endocrine system                | 2.7301  | 0.0321        |
| Prolactin signaling pathway         | Endocrine system                | 10.2781 | 0.0001        |
| Estrogen signaling pathway          | Endocrine system                | 4.8535  | 0.0067        |
| Steroid hormone biosynthesis        | Lipid metabolism                | 3.5659  | 0.0302        |
| TNF signaling pathway               | Signal transduction             | 2.9615  | 0.0426        |
| Metabolism of xenobiotics by P450   | Xenobiotics biodegradation & metabolism | 2.5508  | 0.0383        |

3.2.1. ER Regulated Processes

This category contains two pathways: prolactin signaling pathway and tryptophan metabolism pathway. Prolactin is a polypeptide hormone that binds to prolactin receptors. The expression of...
prolactin is modulated by estrogen [48]. The 22 flavonoids are ER binders and thus impact the prolactin signaling pathway like estrogens through modulating prolactin expression. Since ER is known to regulate tryptophan hydroxylase [51], it is rational that the subsequent biological process of ER binders incorporates tryptophan metabolism. In addition, tryptophan is a precursor to the neurotransmitters serotonin and melatonin [52]. Flavonoids with ER-binding activity may also influence the biological processes related to neurotransmitters serotonin and melatonin such as the circadian clock controlled by melatonin [53]. In this pathway, two common targets (CYP1A1, CYP1B2) are directly involved in the metabolism of melatonin.

3.2.2. Estrogen Metabolism and Synthesis

This category consists of three pathways: ovarian steroidogenesis, steroid hormones biosynthesis, and metabolism of xenobiotics by cytochrome CYP450. Ovarian steroidogenesis comprises two processes: converting cholesterol to androgens and transforming androgens into estrogens. Since the 22 flavonoids are ER binders, they may influence the concentration balances between endogenous estrogens and androgens [54]. In this pathway, CYP1A1, CYP1B1 and CYP19A1 are involved in the biosynthesis of estrogens. Steroid hormone biosynthesis [55] is the process of generating three groups of steroids (C21, C19, C18) from cholesterol, in two major steps. In the first step, the C27 compound cholesterol is cleaved into progestogens (C21) by cholesterol side-chain cleavage enzymes. In the second step, progestogens are used for synthesis of glucocorticoids and mineralocorticoids (C21), androgens (C19), and estrogens (C18). The flavonoids with ER-binding activity may influence the biosynthesis of endogenous estrogens through CYP1A1, CYP1B1 and CYP19A1. Generally, estrogens are removed from the body through transformation into estrogenically inactive metabolites. The concentration of estrogens could be regulated by the common targets (CYP1A1 and CYP1B1) in this pathway. Specifically, the estrogenically inactive metabolites of 2-hydroxyestradiol and 4-hydroxyestradiol from estrogens are catalyzed by CYP1A1 and CYP1B1, respectively [56].

3.2.3. Cellular Apoptosis

The last category of pathways involves cellular apoptosis. Estrogen’s role in regulating apoptosis has strong evidence [57,58]. In fact, using high-dose synthetic estrogens for breast cancer has been an effective therapy for four decades. Blocking the endogenous estrogen binding to ER with the antagonist Tamoxifen is another prevalent breast cancer treatment [59]. Tumor necrosis factor (TNF) could induce apoptosis [60] and activate the estrogen signaling pathway [61]. Flavonoids with ER-binding activity may influence cellular apoptosis through Casp3 and TNF-alpha.

3.3. Disease Pathways of the Common Targets

We also investigated the potential disease pathways influenced by the flavonoids’ common targets. After mapping the 14 common targets to the 71 human disease pathways, we found nine common targets that could be involved in the disease pathways. In total, 42 disease pathways contained the common targets of the 22 flavonoids. Table 6 lists 10 disease pathways designated as enriched, having at least two flavonoid targets, with a $p$-value $\leq 0.05$ and $EF \geq 3$. Interestingly, most of them were involved in five disease types: cancer, infectious diseases, neurodegenerative diseases, cardiovascular diseases, endocrine and metabolic diseases.
Table 6. Enriched disease pathways.

| Pathway                          | Category                          | EF      | p Value |
|---------------------------------|-----------------------------------|---------|---------|
| Proteoglycans in cancer         | Cancers                           | 4.0672  | 0.0013  |
| Chemical carcinogenesis         | Cancers                           | 5.5127  | 0.0045  |
| Pertussis                       | Infectious diseases: Bacterial     | 6.1832  | 0.0032  |
| Legionellosis                   | Infectious diseases: Bacterial     | 8.3192  | 0.0014  |
| Amoebiasis                      | Infectious diseases: Parasitic     | 4.3166  | 0.0089  |
| Toxoplasmosis                   | Infectious diseases: Parasitic     | 3.4403  | 0.0166  |
| Hepatitis B                     | Infectious diseases: Viral         | 3.0916  | 0.0222  |
| Amyotrophic lateral sclerosis   | Neurodegenerative diseases         | 8.6331  | 0.0012  |
| Viral myocarditis               | Cardiovascular diseases            | 6.3549  | 0.0030  |
| Non-alcoholic fatty liver disease| Endocrine and metabolic diseases   | 3.0302  | 0.0234  |

3.3.1. Cancer

Several epidemiological studies [4, 62, 63] strongly support flavonoid rich diets as reducing cancer. There are many in vitro and animal experimental data showing associations between cancer risk and flavonoid chemicals such as quercetin [64] and (-)-Epigallocatechin-3-gallate [65]. However, the role of flavonoids in cancer risk remains uncertain as there are very few data in humans available [66]. In the pathway map of “Proteoglycans in cancer”, flavonoids may influence cancer through three different signaling paths. Flavonoids targeting ER could modulate the gene expression of cyclin D1, which could finally control cell growth and survival. In addition, flavonoids can directly control cell apoptosis through its target Casp3. Regulating cell growth through TNF-alpha and CAV1 is another way that flavonoids might affect cancer. In the chemical carcinogenesis process, flavonoids could influence the metabolism of aromatic hydrocarbons, azo-dyes and olefines through CYP1A1 and CYP1B1.

3.3.2. Infectious Diseases

In response to bacterial or parasitic infections, apoptosis would be initiated by the host cells. Such innate immune response could remove the external pathogens at the early stage of infection. Flavonoids could modulate apoptosis by targeting Casp3 in the infection process of pertussis, legionellosis, amoebiasis, toxoplasmosis and hepatitis B. In addition, during the subsequent inflammation process followed by infection, flavonoids could regulate inflammation through TNF-alpha. Some flavonoids also have antimicrobial effects, such as antibacterial [67] and antifungal [68]. For example, oral administration of tryptanthrin and/or kaempferol significantly decreased the numbers of colonies of helicobacter pylori in helicobacter pylori-infected Mongolian gerbils [69].

3.3.3. Neurodegenerative Diseases

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease, causing muscle weakness and atrophy throughout the body. Astrocytes and microglias are involved in the neurodegenerative process of ALS [70, 71]. Flavonoids could regulate the apoptosis of astrocyte through Casp3. In addition, the growth and death of microglial cell could be regulated by flavonoids targeting TNF-alpha. Some polyphenols may have protective effects against cognitive decline [72] and other neurodegenerative diseases. For example, curcumin and apigenin were proposed as promising therapeutics to slow down the progression of Alzheimer’s disease [73].

3.3.4. Cardiovascular Diseases

Epidemiological evidence on the reduction of the CVD risk in high flavonoid diets is very consistent [74]. In a 7-year-follow-up prospective cohort study on 98,469 U.S. adults, five flavonoid chemicals (anthocyanins, flavan-3-ols, flavones, flavonols, and proanthocyanidins) were found to be individually associated with lower risk of fatal CVD [9]. Viral Myocarditis is a cardiac disease
characterized by heart muscle inflammation, as a consequence of viral infection [75]. Flavonoids could modulate the death of infected myocytes via Casp3 and CAV1 in the early stage of viral infection.

3.3.5. Endocrine and Metabolic Diseases

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with lipid deposition and inflammation in hepatocytes. Insulin resistance is an important factor for progressive steatohepatitis in NAFLD [76]. Flavonoids could influence the hepatocyte insulin resistance via TNF-alpha. In addition, the apoptosis of injured hepatocytes could be induced by flavonoids targeting Casp3. There is also a lot of evidence of the protective role of flavonoids against diabetes [77]. Oral administration of rutin (100 mg/kg) to diabetic rats for a period of 45 days decreased plasma glucose and increased insulin level by altering glycolytic and gluconeogenic enzymes [78]. Treatment with isoquercetin at dose 200 mg/kg was found to decrease blood glucose concentration in diabetic KK-Ay mice [79].

4. Discussion

Chemicals exert their biological functions through binding or interacting with the targets. The overall target characteristics of flavonoids that bind ER may provide clues for more fully delineating their risk versus benefit profiles. Identifying the targets beyond ER itself is the starting place. Molecular docking [80–83], machine learning [84,85], text mining and network inference [86,87] are among the many sound computational methods for predicting alternate targets of chemicals. However, a high false positive rate is a side effect of most approaches, and a main reason we chose to use only manually curated targets from CTD and HIT. While the more meager data increasing the likelihood of missing flavonoid pathway associations, we deemed developing a more trustworthy association profile more important. Among the 22 estrogenic flavonoids we included, only 11 and 17 of them are covered by HIT and CTD, respectively, with 14 common flavonoid targets. The commonality restriction we imposed enhances true positive rate and the validity of the final pathway association profile. Even with the more rigorous screening of the data, abundant and biologically rational conclusions were made with no contradictions to existing science.

Pathways are manually curated series of molecular interactions that encode diverse research results that converge and elucidate a complex biological process connecting molecular entities and events. As long as more and better data are forthcoming, pathways will increasingly encompass the vital interconnections that are the basis of life. Pathway enrichment analyses provide a means for disentangling more accurately the true biology in a system so complex that false random solutions abound. In our present work, we have applied reasoning to filter data to increase actual cause and effect and reduce random correlations, in this case to help reveal the multiple biological meanings and actions associated with flavonoids, based on knowledge about their molecular targets. According to our pathway enrichment results, CYP1A1, CYP1B1, CYP19A1, Casp3, TNF-alpha are genes associated with multiple pathways having substantial cross talk. For example, CYP1A1, CPY1A2 could participate in estrogen metabolism and biosynthesis as well as tryptophan metabolism. Casp3’s and TNF-alpha’s apoptosis suggest their affiliation with the pathological development of across several diseases. Flavonoids could regulate the cell death of astrocytes and microglia in brain, myocytes in heart, as well as cancer cells or abnormal or injured cells. Given that apoptosis is ubiquitous in biological process across cell types, risks incurred with flavonoid doses higher than what humans have evolved with should be concerning and more carefully studied. Indeed, several identified pathways based on targets in CTD and HIT had already been validated by previous studies of flavonoids compounds. For example, apigenin can induce the apoptosis process of NCI-H460 cells by up-regulating expression of Bax and Casp3 and down-regulating the expression of Bel-2 [88]. Quercetin was shown to significantly inhibit hepatitis B virus replication and hepatitis B surface antigen secretion in human hepatoma cell lines: HepG2.2.15 cell and HuH-7 cell [89]. (-)-Epigallocatechin-3-gallate (EGCG) displayed the neuroprotective effects on the transgenic mouse model of amyotrophic lateral sclerosis [90].
In addition, co-incubation with lamivudine (3TC), entecavir (ETV), or adefovir (Ade) further enhanced the quercetin-induced inhibition of Hepatitis B virus (HBV) replication. This inhibition was partially associated with decreased heat shock proteins and HBV transcription levels. The results indicate that quercetin inhibited HBV antigen secretion and genome replication in human hepatoma cell lines, which suggests that quercetin may be a potentially effective anti-HBV agent.

5. Conclusions

Here, we used pathway enrichment analysis on carefully vetted data to derive a profile of potential risk associated with 22 flavonoids that bind highly conserved estrogen receptor nuclear proteins. To improve the likelihood of enriched pathways with true positives, we restricted data to 14 targets of flavonoids identified by both CTD and HIT manually curated databases. Enriched pathways of targets were found to be mainly involved in three paramount biological process types, ER regulated processes, estrogens’ metabolism and synthesis, and as well as apoptosis. Among the findings is a cause for concern that flavonoids via apoptosis pathways could be especially important for cancer, infection, amyotrophic lateral sclerosis, viral myocarditis and non-alcoholic fatty liver disease. Further attention should be paid to potential apoptosis effects of flavonoids that bind ERs. The approach we present should provide ever improving clues to potential risk posed by the important flavonoids that have long been a component of human food, and that is now prominent in food supplements at doses far above historical norms.

Acknowledgments: This research was supported in part by an appointment to the Research Participation Program at the National Center for Toxicological Research (Hao Ye, Hui Wen Ng, Sugunadevi Sakkiah) administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration.

Author Contributions: Huixiao Hong conceived and designed the study; Hao Ye curated the experimental data; Huixiao Hong, Hao Ye, Sugunadevi Sakkiah and Hui Wen Ng conducted the calculations and developed the models. Weigong Ge, Roger Perkins and Weida Tong contributed to the data analysis. Huixiao Hong, Roger Perkins and Hao Ye wrote the first draft of the manuscript. All authors contributed to writing the manuscript.

Conflicts of Interest: The authors declare no conflict of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Food and Drug Administration.

Abbreviations

The following abbreviations are used in this manuscript:

| Abbreviation | Definition |
|--------------|------------|
| ABC          | ATP-Binding Cassette |
| ALS          | Amyotrophic Lateral Sclerosis |
| CTD          | Comparative Toxicogenomics Database |
| EADB         | Estrogenic Activity Database |
| EDSP         | Endocrine Disruptor Screening Program |
| EMA          | European Medicines Agency |
| EPA          | Environmental Protection Agency |
| ER           | Estrogen Receptor |
| FDA          | Food and Drug Administration |
| HIT          | Herbal Ingredients' Target |
| NAFLD        | Non-alcoholic Fatty Liver Disease |
| KEGG         | Kyoto Encyclopedia of Genes and Genomes |
| EGCG         | (-)-Epigallocatechin-3-Gallate |
References

1. Ververidis, F.; Trantas, E.; Douglas, C.; Vollmer, G.; Kretzschmar, G.; Panopoulos, N. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health. Biotechnol. J. 2007, 2, 1214. [CrossRef] [PubMed]

2. Paul, E.; Szmitko, B.S.V. Cardiology patient page red wine and your heart. Circulation 2005, 111–119.

3. Hui, C.; Qi, X.; Qianyong, Z.; Xiaoli, P.; Jundong, Z.; Mantian, M. Flavonoids, flavonoid subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. PLoS ONE 2013, 8, e54318. [CrossRef] [PubMed]

4. Romagnolo, D.F.; Selmin, O.I. Flavonoids and cancer prevention: A review of the evidence. J. Nutr. Gerontol. Geriatr. 2012, 31, 206–238. [CrossRef] [PubMed]

5. Park, E.J.; Pezzuto, J.M. Flavonoids in cancer prevention. Anti-Cancer Agents Med. Chem. 2012, 12, 836–851. [CrossRef]

6. Choudhary, R.K.; Swarnkar, P.L. Antioxidant activity of phenolic and flavonoid compounds in some medicinal plants of India. Nat. Prod. Res. 2011, 25, 1101–1109. [CrossRef] [PubMed]

7. Sen, S.; De, B.; Devanna, N.; Chakraborty, R. Total phenolic, total flavonoid content, and antioxidant capacity of the leaves of meyna spinosa roxb., an Indian medicinal plant. Chin. J. Nat. Med. 2013, 11, 149–157. [CrossRef]

8. Rangel-Huerta, O.D.; Pastor-Villaescusa, B.; Aguilera, C.M.; Gil, A. A systematic review of the efficacy of bioactive compounds in cardiovascular disease: Phenolic compounds. Nutrients 2015, 7, 5177–5216. [CrossRef] [PubMed]

9. McCullough, M.L.; Peterson, J.J.; Patel, R.; Jacques, P.F.; Shah, R.; Dwyer, J.T. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of U.S. adults. Am. J. Clin. Nutr. 2012, 95, 454–464. [CrossRef] [PubMed]

10. Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. Proc. Nutr. Soc. 2010, 69, 273–278. [CrossRef] [PubMed]

11. Hurt, R.T.; Wilson, T. Geriatric obesity: Evaluating the evidence for the use of flavonoids to promote weight loss. J. Nutr. Gerontol. Geriatr. 2012, 31, 269–289. [CrossRef] [PubMed]

12. Williams, R.J.; Spencer, J.P. Flavonoids, cognition, and dementia: Actions, mechanisms, and potential therapeutic utility for alzheimer disease. Free Radic. Biol. Med. 2012, 52, 35–45. [CrossRef] [PubMed]

13. Chen, J.H.; Zhang, N.; Wang, Y.Q.; Wang, J.Z.; Ji, S.X.; Dang, W.J.; Li, S.M.; Feng, L. Estrogenic effects of flavonoid components in xiaoyao powder. Genet. Mol. Res. GMR 2016, 15. [CrossRef] [PubMed]

14. Resende, F.A.; de Oliveira, A.P.; de Camargo, M.S.; Villegas, W.; Varanda, E.A. Evaluation of estrogenic potential of flavonoids using a recombinant yeast strain and mcf7/bus cell proliferation assay. PLoS ONE 2013, 8, e74881. [CrossRef] [PubMed]

15. Dietary Supplements. Available online: http://www.fda.gov/Food/DietarySupplements/ (accessed on 11 February 2016).

16. Quercetin. Available online: https://examine.com/supplements/quercetin/ (accessed on 11 February 2016).

17. Soy Isoflavones. Available online: https://examine.com/supplements/soy-isoflavones/ (accessed on 11 February 2016).

18. Brazier, N.C.; Levine, M.A. Understanding drug–herb interactions. Pharmacoepidemiol. Drug Saf. 2003, 12, 427–430. [CrossRef] [PubMed]

19. Morris, M.E.; Zhang, S. Flavonoid-drug interactions: Effects of flavonoids on abc transporters. Life Sci. 2006, 78, 2116–2130. [CrossRef] [PubMed]

20. Li, Y.; Paxton, J.W. The effects of flavonoids on the abc transporters: Consequences for the pharmacokinetics of substrate drugs. Expert Opin. Drug Metab. Toxicol. 2013, 9, 267–285. [CrossRef] [PubMed]

21. Bircsak, K.M.; Aleksunes, L.M. Interaction of isoflavones with the bcrp/abcg2 drug transporter. Curr. Drug Metab. 2015, 16, 124–140. [CrossRef] [PubMed]

22. Power, D.; Llewellyn, L.; Faustino, M.; Nowell, M.A.; Björnsson, B.T.; Einarsdottir, I.; Canario, A.V.; Sweeney, G.E. Thyroid hormones in growth and development of fish. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2001, 130, 447–459. [CrossRef]

23. Gilbert, L.I.; King, D.S. Physiology of growth and development: Endocrine aspects. Physiol. Insecta 1973. [CrossRef]
24. Ojamaa, K.; Klemperer, J.D.; Klein, I. Acute effects of thyroid hormone on vascular smooth muscle. *Thyroid* 1996, 6, 505–512. [CrossRef] [PubMed]

25. Van Leeuwen, F.; Den Tonkelaar, E.; Van Logten, M. Toxicity of sodium bromide in rats: Effects on endocrine system and reproduction. *Food Chem. Toxicol.* 1983, 21, 383–389. [CrossRef]

26. Endocrine Disruption. Available online: http://www.epa.gov/endocrine-disruption (accessed on 11 February 2016).

27. Lee, H.-R.; Kim, T.-H.; Choi, K.-C. Functions and physiological roles of two types of estrogen receptors, erα and erβ, identified by estrogen receptor knockout mouse. *Lab. Anim. Res.* 2012, 28, 71–76. [CrossRef] [PubMed]

28. Swedenborg, E.; Power, K.A.; Cai, W.; Pongratz, I.; Rüegg, J. Regulation of estrogen receptor beta activity and implications in health and disease. *Cell. Mol. Life Sci.* 2009, 66, 3873–3894. [CrossRef] [PubMed]

29. Wise, P.M.; Dubal, D.B.; Wilson, M.E.; Rau, S.W.; Böttner, M. Minireview: Neuroprotective effects of estrogen—New insights into mechanisms of action. *Endocrinology* 2001, 142, 969–973. [PubMed]

30. Garcia-Segura, L.M.; Azcoitia, I.; DonCarlos, L.L. Neuroprotection by estradiol. *Prog. Neurobiol.* 2001, 63, 29–60. [CrossRef]

31. Palmieri, C.; Cheng, G.; Saji, S.; Zelada-Hedman, M.; Weihua, Z.; Van Noorden, S.; Wahlstrom, T.; Coombes, R.; Warner, M.; Gustafsson, J. Estrogen receptor beta in breast cancer. *Endocr. Relat. Cancer* 2002, 9, 1–13. [CrossRef] [PubMed]

32. Hall, J.M.; Korach, K.S. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. *Mol. Endocrinol.* 2003, 17, 792–803. [CrossRef] [PubMed]

33. Pare, G.; Krust, A.; Karas, R.H.; Dupont, S.; Aronovitz, M.; Chambon, P.; Mendelsohn, M.E. Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. *Circ. Res.* 2002, 90, 1087–1092. [CrossRef] [PubMed]

34. Murphy, E. Estrogen signaling and cardiovascular disease. *Circ. Res.* 2011, 109, 687–696. [CrossRef] [PubMed]

35. Ohlsson, C.; Hellberg, N.; Parini, P.; Vidal, O.; Bohlolooy, M.; Rudling, M.; Lindberg, M.K.; Warner, M.; Angelin, B.; Gustafsson, J.-Å. Obesity and disturbed lipoprotein profile in estrogen receptor-α-deficient male mice. *Biochem. Biophys. Res. Commun.* 2000, 278, 640–645. [CrossRef] [PubMed]

36. Haas, E.; Bhattacharya, I.; Brailoiu, E.; Damjanović, M.; Brailoiu, G.C.; Gao, X.; Mueller-Guerré, L.; Marjon, N.A.; Güt, A.; Minotti, R. Regulatory role of g protein-coupled estrogen receptor for vascular function and obesity. *Circ. Res.* 2009, 104, 288–291. [CrossRef] [PubMed]

37. Gennari, L.; Merlotti, D.; Valleggi, F.; Martini, G.; Nuti, R. Selective estrogen receptor modulators for postmenopausal osteoporosis. *Drugs Aging* 2007, 24, 361–379. [CrossRef] [PubMed]

38. Shen, J.; Xu, L.; Fang, H.; Richard, A.M.; Bray, J.D.; Judson, R.S.; Zhou, G.; Colatsky, T.J.; Aungst, J.L.; Teng, C. Eadb: An estrogenic activity database for assessing potential endocrine activity. *Toxicol. Sci.* 2013, 135, 277–291. [CrossRef] [PubMed]

39. Hong, H.; Branham, W.S.; Ng, H.W.; Moland, C.L.; Dial, S.L.; Fang, H.; Perkins, R.; Sheehan, D.; Tong, W. Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein. *Toxicol. Sci.* 2015, 143, 333–348. [CrossRef] [PubMed]

40. Mattingly, C.; Rosenstein, M.; Colby, G.; Forrest, J., Jr.; Boyer, J. The comparative toxicogenomics database (ctd): A resource for comparative toxicological studies. *J. Exp. Zool. Part A Comp. Exp. Biol.* 2006, 305, 689. [CrossRef] [PubMed]

41. Ye, H.; Ye, L.; Kang, H.; Zhang, D.; Tao, L.; Tang, K.; Liu, X.; Zhu, R.; Liu, Q.; Chen, Y. Hit: Linking herbal active ingredients to targets. *Nucleic Acids Res.* 2011, 39, 1055–1059. [CrossRef] [PubMed]

42. Kanehisa, M.; Goto, S. Kegg: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000, 28, 27–30. [CrossRef] [PubMed]

43. Khatri, P.; Sirot, A.; Butte, A.J. Ten years of pathway analysis: Current approaches and outstanding challenges. *PLoS Comput. Biol.* 2012, 8, e1002375. [CrossRef] [PubMed]

44. Ye, H.; Tang, K.; Yang, L.; Cao, Z.; Li, Y. Study of drug function based on similarity of pathway fingerprint. *Protein Cell* 2012, 3, 132–139. [CrossRef] [PubMed]
45. Evangelou, M.; Rendon, A.; Ouwehand, W.H.; Wernisch, L.; Dudbridge, F. Comparison of methods for competitive tests of pathway analysis. PLoS ONE 2012, 7, e41018. [CrossRef] [PubMed]

46. Tong, W.; Cao, X.; Harris, S.; Sun, H.; Fang, H.; Fuscoe, J.; Harris, A.; Hong, H.; Xie, Q.; Perkins, R.; Shi, L.; Casciano, D. ArrayTrack—Supporting toxicogenomic research at the U.S. food and drug administration national center for toxicological research. Environ. Health Perspect. 2003, 111, 1819–1826. [CrossRef] [PubMed]

47. Ye, H.; Yang, L.; Cao, Z.; Tang, K.; Li, Y. A pathway profile-based method for drug repositioning. Chin. Sci. Bull. 2012, 57, 2106–2112. [CrossRef]

48. Watters, J.J.; Chun, T.Y.; Kim, Y.N.; Bertics, P.; Gorski, J. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol. Endocrinol. 2000, 14, 1872–1881. [CrossRef] [PubMed]

49. Chemical-Gene Interaction Query. Available online: http://ctdbase.org/query.go?type=ixn (accessed on 22 October 2015).

50. HIT: Herbal Ingredients’ Targets Database. Available online: http://lifecenter.sgst.cn/hit (accessed on 22 October 2015).

51. Hiroi, R.; Handa, R.J. Estrogen receptor-β regulates human tryptophan hydroxylase-2 through an estrogen response element in the S’ untranslated region. J. Neurochem. 2013, 127, 487–495. [CrossRef] [PubMed]

52. Slominski, A.; Semak, I.; Pisarchik, A.; Sweatman, T.; Szczesniewski, A.; Wortsman, J. Conversion of l-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002, 511, 102–106. [CrossRef]

53. Altun, A.; Ugur-Altun, B. Melatonin: Therapeutic and clinical utilization. Int. J. Clin. Pract. 2007, 61, 835–845. [CrossRef] [PubMed]

54. Harris, R.M.; Wood, D.M.; Bottomley, L.; Blagg, S.; Owen, K.; Hughes, P.J.; Waring, R.H.; Kirk, C.J. Phytoestrogens are potent inhibitors of estrogen sulfation: Implications for breast cancer risk and treatment. J. Clin. Endocrinol. Metab. 2004, 89, 1779–1787. [CrossRef] [PubMed]

55. Häggström, M. Diagram of the pathways of human steroidogenesis. Medicine 2014, 1, 1. [CrossRef]

56. Tsuchiya, Y.; Nakajima, M.; Yokoi, T. Cytochrome p450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005, 227, 115–124. [CrossRef] [PubMed]

57. Jordan, V.C. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 2015, 22, 1–31. [CrossRef] [PubMed]

58. Lewis-Wambi, J.S.; Jordan, V.C. Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit. Breast Cancer Res 2009, 11, 206. [CrossRef] [PubMed]

59. Jordan, V.C. Tamoxifen (ici46, 474) as a targeted therapy to treat and prevent breast cancer. Brit. J. Pharmacol. 2006, 147, S269–S276. [CrossRef] [PubMed]

60. Rath, P.C.; Aggarwal, B.B. Tnf-induced signaling in apoptosis. J. Clin. Immunol. 1999, 19, 350–364. [CrossRef] [PubMed]

61. Gori, I.; Pellegrini, C.; Staedler, D.; Russell, R.; Jan, C.; Canny, G.O. Tumor necrosis factor-alpha activates estrogen signaling pathways in endometrial epithelial cells via estrogen receptor alpha. Mol. Cell. Endocrinol. 2011, 345, 27–37. [CrossRef] [PubMed]

62. Mursu, J.; Nurmi, T.; Tuomainen, T.P.; Salonen, J.T.; Pukkala, E.; Voutilainen, S. Intake of flavonoids and risk of cancer in finnish men: The kuopio ischaemic heart disease risk factor study. Int. J. Cancer 2008, 123, 660–663. [CrossRef] [PubMed]

63. Deng, X.H.; Song, H.Y.; Zhou, Y.F.; Yuan, G.Y.; Zheng, F. Effects of quercetin on the proliferation of breast cancer cells and expression of survivin. Exp. Ther. Med. 2013, 6, 1155–1158. [PubMed]

64. Yokoyama, S.; Hirano, H.; Wakimaru, N.; Sarker, K.P.; Kuratsu, J. Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro. Neuro-Oncology 2001, 3, 22–28. [CrossRef] [PubMed]

65. Zamora-Ros, R.; Touillaud, M.; Rothwell, J.A.; Romieu, I.; Scalbert, A. Measuring exposure to the polyphenol metabolome in observational epidemiologic studies: Current tools and applications and their limits. Am. J. Clin. Nutr. 2014, 100, 11–26. [CrossRef] [PubMed]
67. Hanski, L.; Genina, N.; Uvell, H.; Malinovskaja, K.; Gyilfe, A.; Laaksonen, T.; Kolakovic, R.; Makila, E.; Salonen, J.; Hirvonen, J. et al. Inhibitory activity of the isoflavone biochanin a on intracellular bacteria of genus chlamydia and initial development of a buccal formulation. *PLoS ONE* **2014**, *9*, e115115. [CrossRef] [PubMed]

68. das Neves, M.V.; da Silva, T.M.; Lima Ede, O.; da Cunha, E.V.; Oliveira Ede, J. Isoflavone formononetin from red propolis acts as a fungicide against candida sp. *Braz. J. Microbiol.* **2016**, *47*, 159–166. [CrossRef] [PubMed]

69. Kataoka, M.; Hirata, K.; Kunikata, T.; Ushio, S.; Iwaki, K.; Ohashi, K.; Ikeda, M.; Kurimoto, M. Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (*polygonum tinctorium* lour.), against *helicobacter pylori*-infected mongolian gerbils. *J. Gastroenterol.* **2001**, *36*, 5–9. [CrossRef] [PubMed]

70. Frakes, A.E.; Ferraiuolo, L.; Haidet-Phillips, A.M.; Schmelzer, L.; Braun, L.; Miranda, C.J.; Ladner, K.J.; Bevan, A.K.; Foust, K.D.; Godbout, J.P. Microglia induce motor neuron death via the classical *nf-kb* pathway in amyotrophic lateral sclerosis. *Neuron* **2014**, *81*, 1009–1023. [CrossRef] [PubMed]

71. Haidet-Phillips, A.M.; Hester, M.E.; Miranda, C.J.; Meyer, K.; Braun, L.; Frakes, A.; Song, S.; Likhite, S.; Murtha, M.J.; Foust, K.D. Astrocytes from familial and sporadic als patients are toxic to motor neurons. *Nat. Biotechnol.* **2011**, *29*, 824–828. [CrossRef] [PubMed]

72. Rabassa, M.; Cherubini, A.; Zamora-Ros, R.; Urpi-Sarda, M.; Bandinelli, S.; Ferrucci, L.; Andres-Lacueva, C. Low levels of a urinary biomarker of dietary polyphenol are associated with substantial cognitive decline over a 3-year period in older adults: The invecechiare in chianti study. *J. Am. Geriatr. Soc.* **2015**, *63*, 938–946. [CrossRef] [PubMed]

73. Venigalla, M.; Gyengesi, E.; Munch, G. Curcumin and apigenin-novel and promising therapeutics against chronic neuroinflammation in alzheimer’s disease. *Neural Regen. Res.* **2015**, *10*, 1181–1185. [PubMed]

74. Cassidy, A.; Mukamal, K.J.; Liu, L.; Franz, M.; Eliassen, A.H.; Rimm, E.B. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. *Circulation* **2013**, *127*, 188–196. [CrossRef] [PubMed]

75. Yajima, T.; Knowlton, K.U. Viral myocarditis from the perspective of the virus. *Circulation* **2009**, *119*, 2615–2624. [CrossRef] [PubMed]

76. Utschneider, K.M.; Kahn, S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. *J. Clin. Endocrinol. Metab.* **2006**, *91*, 4753–4761. [CrossRef] [PubMed]

77. Zamora-Ros, R.; Forouhi, N.G.; Sharp, S.J.; Gonzalez, C.A.; van der Schouw, Y.T.; Amiano, P.; Boehning, H.; Bredsdorff, L.; et al. The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in european populations: The epic-interact study. *Diabetes Care* **2013**, *36*, 3961–3970. [CrossRef] [PubMed]

78. Stanley Mainzen Prince, P.; Kamalakkannan, N. Rutin improves glucose homeostasis in streptozotocin diabetic tissues by altering glycolytic and gluconeogenic enzymes. *J. Biochem. Mol. Toxicol.* **2006**, *20*, 96–102. [CrossRef] [PubMed]

79. Zhang, R.; Yao, Y.; Wang, Y.; Ren, G. Antidiabetic activity of isovercurcin in diabetic kk-ay mice. *Nutr. Metab.* **2011**, *8*, 85. [CrossRef] [PubMed]

80. Ng, H.W.; Zhang, W.; Shu, M.; Luo, H.; Ge, W.; Perkins, R.; Tong, W.; Hong, H. Competitive molecular docking model for predicting estrogen receptor agonists and antagonists. *BMC Bioinf.* **2014**, *15*, S4. [CrossRef] [PubMed]

81. Luo, H.; Du, T.; Zhou, P.; Yang, L.; Mei, H.; Ng, H.W.; Zhang, W.; Shu, M.; Tong, W.; Shi, L.; et al. Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting potential idiosyncratic drug reactions. *Comb. Chem. High Throughput Screen.* **2015**, *18*, 296–304. [CrossRef] [PubMed]

82. Shen, J.; Zhang, W.; Fang, H.; Perkins, R.; Tong, W.; Hong, H. Homology modeling, molecular docking, and molecular dynamics simulations elucidated alpha-fetoprotein binding modes. *BMC Bioinform.* **2013**, *14*, S6. [CrossRef] [PubMed]

83. Shu, M.; Ng, H.W.; Orr, M.; Luo, H.; Ye, H.; Ge, W.; Tong, W.; Hong, H. Homology model and ligand binding interactions of the extracellular domain of the human αβ2 nicotinic acetylcholine receptor. *J. Biomed. Sci. Eng.* **2016**, *9*, 41–100.

84. Luo, H.; Ye, H.; Ng, H.W.; Shi, L.; Tong, W.; Mendrick, D.L.; Hong, H. Machine learning methods for predicting HLA-peptide binding activity. *Bioinform. Biol. Insights* **2015**, *9*, 21–29. [PubMed]
85. Hong, H.; Hong, Q.; Perkins, R.; Shi, L.; Fang, H.; Su, Z.; Dragan, Y.; Fuscoe, J.C.; Tong, W. The accurate prediction of protein family from amino acid sequence by measuring features of sequence fragments. *J. Comput. Biol.* 2009, 16, 1671–1688. [CrossRef] [PubMed]

86. Luo, H.; Ye, H.; Ng, H.W.; Shi, L.; Tong, W.; Mattes, W.; Mendrick, D.L.; Hong, H. Understanding and predicting binding between human leukocyte antigens and peptides by network analysis. *BMC Bioinform.* 2015, 16, S9. [CrossRef] [PubMed]

87. Ye, H.; Luo, H.; Ng, H.W.; Meehan, J.; Ge, W.; Tong, W.; Hong, H. Applying network analysis and Nebula (neighbor-edges based and unbiased leverage algorithm) to ToxCast data. *Environ. Int.* 2016, 88–89, 81–92. [CrossRef] [PubMed]

88. Pan, X.; Yang, Z.; Yang, Z.; Zhou, S.; Zhang, H.; Zang, L. Effect of apigenin on proliferation and apoptosis of human lung cancer nci-h460 cells. *J. South. Med. Univ.* 2013, 33, 1137–1140.

89. Cheng, Z.; Sun, G.; Guo, W.; Huang, Y.; Sun, W.; Zhao, F.; Hu, K. Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines. *Virol. Sin.* 2015, 30, 261–268. [CrossRef] [PubMed]

90. Xu, Z.; Chen, S.; Li, X.; Luo, G.; Li, L.; Le, W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. *Neurochem. Res.* 2006, 31, 1263–1269. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).